Literature DB >> 31429063

Selinexor: First Global Approval.

Yahiya Y Syed1.   

Abstract

Selinexor (XPOVIO™) is a first-in-class, oral, small molecule Exportin-1 (XPO1) inhibitor that is being developed by Karyopharm Therapeutics for the treatment of cancer. Selinexor (in combination with dexamethasone) received accelerated approval in the USA in July 2019 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). Selinexor is also undergoing clinical development in a wide range of haematological and solid cancers. This article summarizes the milestones in the development of selinexor leading to this first approval for RRMM.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31429063     DOI： 10.1007/s40265-019-01188-9

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  26 in total

1.  First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

Authors:  Albiruni R Abdul Razak; Morten Mau-Soerensen; Nashat Y Gabrail; John F Gerecitano; Anthony F Shields; Thaddeus J Unger; Jean R Saint-Martin; Robert Carlson; Yosef Landesman; Dilara McCauley; Tami Rashal; Ulrik Lassen; Richard Kim; Lee-Anne Stayner; Mansoor R Mirza; Michael Kauffman; Sharon Shacham; Amit Mahipal
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

2.  Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.

Authors:  Y Zhong; D El-Gamal; J A Dubovsky; K A Beckwith; B K Harrington; K E Williams; V M Goettl; S Jha; X Mo; J A Jones; J M Flynn; K J Maddocks; L A Andritsos; D McCauley; S Shacham; M Kauffman; J C Byrd; R Lapalombella
Journal:  Leukemia       Date:  2014-01-13       Impact factor: 11.528

3.  Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.

Authors:  Fabio Conforti; Xu Zhang; Guanhua Rao; Tommaso De Pas; Yoko Yonemori; Jose Antonio Rodriguez; Justine N McCutcheon; Raneen Rahhal; Anna T Alberobello; Yisong Wang; Yu-Wen Zhang; Udayan Guha; Giuseppe Giaccone
Journal:  Cancer Res       Date:  2017-08-17       Impact factor: 12.701

4.  A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

Authors:  Ramiro Garzon; Michael Savona; Rachid Baz; Michael Andreeff; Nashat Gabrail; Martin Gutierrez; Lynn Savoie; Paul Morten Mau-Sorensen; Nina Wagner-Johnston; Karen Yee; Thaddeus J Unger; Jean-Richard Saint-Martin; Robert Carlson; Tami Rashal; Trinayan Kashyap; Boris Klebanov; Sharon Shacham; Michael Kauffman; Richard Stone
Journal:  Blood       Date:  2017-03-23       Impact factor: 22.113

5.  Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

Authors:  John Kuruvilla; Michael Savona; Rachid Baz; Paul Morten Mau-Sorensen; Nashat Gabrail; Ramiro Garzon; Richard Stone; Michael Wang; Lynn Savoie; Peter Martin; Ian Flinn; Meagan Jacoby; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Sharon Friedlander; Robert Carlson; Michael Kauffman; Sharon Shacham; Martin Gutierrez
Journal:  Blood       Date:  2017-05-03       Impact factor: 22.113

6.  Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Authors:  Nizar J Bahlis; Heather Sutherland; Darrell White; Michael Sebag; Suzanne Lentzsch; Rami Kotb; Christopher P Venner; Cristina Gasparetto; Aldo Del Col; Paola Neri; Donna Reece; Michael Kauffman; Sharon Shacham; T J Unger; Jacqueline Jeha; Jean-Richard Saint-Martin; Jatin Shah; Christine Chen
Journal:  Blood       Date:  2018-10-23       Impact factor: 22.113

Review 7.  Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.

Authors:  Ujjawal H Gandhi; William Senapedis; Erkan Baloglu; Thaddeus J Unger; Ajai Chari; Dan Vogl; Robert F Cornell
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-03-14

8.  Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.

Authors:  Trinayan Kashyap; Christian Argueta; Amro Aboukameel; Thaddeus John Unger; Boris Klebanov; Ramzi M Mohammad; Irfana Muqbil; Asfar S Azmi; Claire Drolen; William Senapedis; Margaret Lee; Michael Kauffman; Sharon Shacham; Yosef Landesman
Journal:  Oncotarget       Date:  2016-11-29

9.  A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.

Authors:  Michael Shafique; Roohi Ismail-Khan; Martine Extermann; Dan Sullivan; Dawn Goodridge; David Boulware; Deanna Hogue; Hatem Soliman; Hung Khong; Hyo S Han
Journal:  Oncologist       Date:  2019-04-17

10.  Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.

Authors:  Irfana Muqbil; Amro Aboukameel; Sivan Elloul; Robert Carlson; William Senapedis; Erkan Baloglu; Michael Kauffman; Sharon Shacham; Divaya Bhutani; Jeffrey Zonder; Asfar S Azmi; Ramzi M Mohammad
Journal:  Cancer Lett       Date:  2016-09-28       Impact factor: 8.679
View more
  18 in total

Review 1.  Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Viruses       Date:  2020-09-26       Impact factor: 5.048

2.  UPLC-MS/MS Measurement of the Effect of Isavuconazole, Itraconazole and Fluconazole on the Pharmacokinetics of Selinexor in Rats.

Authors:  Shuang-Long Li; Yi Zhang; Qian-Shi Cheng; Jun-Zhe Xin; Ze-Qin Dong; Xiang-Jun Qiu
Journal:  Infect Drug Resist       Date:  2020-09-14       Impact factor: 4.003

3.  Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment.

Authors:  Jun-Yi Zhu; Jin-Gu Lee; Joyce van de Leemput; Hangnoh Lee; Zhe Han
Journal:  Cell Biosci       Date:  2021-03-25       Impact factor: 7.133

4.  Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor.

Authors:  Jin-Gu Lee; Weiliang Huang; Hangnoh Lee; Joyce van de Leemput; Maureen A Kane; Zhe Han
Journal:  Cell Biosci       Date:  2021-03-25       Impact factor: 7.133

Review 5.  FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review.

Authors:  Aleksandra Sochacka-Ćwikła; Marcin Mączyński; Andrzej Regiec
Journal:  Cancers (Basel)       Date:  2021-12-24       Impact factor: 6.639

Review 6.  Overview of Ocular Side Effects of Selinexor.

Authors:  Nagham Al-Zubidi; Dan S Gombos; David S Hong; Vivek Subbiah; Siqing Fu; Jordi Rodon Ahnert; Sarina A Piha-Paul; Apostolia M Tsimberidou; Daniel D Karp; Funda Meric Bernstam; Aung Naing
Journal:  Oncologist       Date:  2021-04-08

7.  miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer.

Authors:  Silvia Martini; Valentina Zuco; Monica Tortoreto; Stefano Percio; Elisa Campi; Rihan El Bezawy; Valentina Doldi; Yosef Landesman; Marzia Pennati; Nadia Zaffaroni
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-29

8.  Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody.

Authors:  Silvia Martini; Mariangela Figini; Aurora Croce; Barbara Frigerio; Marzia Pennati; Alessandro Massimo Gianni; Cinzia De Marco; Maria Grazia Daidone; Christian Argueta; Yosef Landesman; Nadia Zaffaroni; Alessandro Satta
Journal:  Cells       Date:  2020-10-02       Impact factor: 6.600

Review 9.  Repurposing anticancer drugs for the management of COVID-19.

Authors:  Khalid El Bairi; Dario Trapani; Angelica Petrillo; Cécile Le Page; Hanaa Zbakh; Bruno Daniele; Rhizlane Belbaraka; Giuseppe Curigliano; Said Afqir
Journal:  Eur J Cancer       Date:  2020-09-22       Impact factor: 9.162

Review 10.  Therapeutic Targeting of Exportin-1 in Childhood Cancer.

Authors:  Basia Galinski; Thomas B Alexander; Daniel A Mitchell; Hannah V Chatwin; Chidiebere Awah; Adam L Green; Daniel A Weiser
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.